probucol has been researched along with Dyslipidemia in 4 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Excerpt | Relevance | Reference |
---|---|---|
"To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.22 | Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Chung, CH; Han, KA; Hwang, YC; Jin, SM; Ko, SH; Lee, HW; Lee, IK; Lee, MK; Nam, MS; Park, IeB; Park, TS; Rhee, EJ; Sohn, TS; Yu, JM, 2016) |
"Regarding patients with familial hypercholesterolemia, those treated with probucol, which is a potent anti-oxidative and anti-hyperlipidemic drug, showed significantly lower Ox-HDL (16." | 1.62 | Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein. ( Inui, H; Kanno, K; Katayama, Y; Koseki, M; Masuda, D; Nishida, M; Ohama, T; Okada, T; Saga, A; Sakata, Y; Sumida, M; Yamashita, S, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Okada, T | 1 |
Sumida, M | 1 |
Ohama, T | 1 |
Katayama, Y | 1 |
Saga, A | 1 |
Inui, H | 1 |
Kanno, K | 1 |
Masuda, D | 1 |
Koseki, M | 1 |
Nishida, M | 1 |
Sakata, Y | 1 |
Yamashita, S | 1 |
Hirata, KI | 1 |
Jin, SM | 1 |
Han, KA | 1 |
Yu, JM | 1 |
Sohn, TS | 1 |
Choi, SH | 1 |
Chung, CH | 1 |
Park, IeB | 1 |
Rhee, EJ | 1 |
Baik, SH | 1 |
Park, TS | 1 |
Lee, IK | 1 |
Ko, SH | 1 |
Hwang, YC | 1 |
Cha, BS | 1 |
Lee, HW | 1 |
Nam, MS | 1 |
Lee, MK | 1 |
Fukumoto, Y | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.[NCT01726816] | Phase 2 | 126 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for probucol and Dyslipidemia
Article | Year |
---|---|
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2016 |
3 other studies available for probucol and Dyslipidemia
Article | Year |
---|---|
Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Topics: Adult; Antioxidants; Atherosclerosis; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Huma | 2021 |
New Evidence of Probucol on Cardiovascular Events.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Dyslipidem | 2021 |
[Medicines for dyslipidemia].
Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart F | 2012 |